China’s Wu Capital leads $91.5m Series A round in genetic firm Korro Bio

Cambridge-based biotech startup Korro Bio has raised $91.5 million in a Series A funding round led by Chinese investment firm Wu Capital to boost its gene-editing therapies.

In a statement, the company said the Series A round was also participated by existing and new investors, including Atlas Ventures, New Enterprise Associates, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, and Alexandria Venture Investments.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter